If this finding is confirmed in future cohorts, the frequency of WNT5A+/IL24+ cells could be monitored in the increasing number of patients receiving biologics, with the potential to inform personalized, drug tapering strategies in psoriasis remission. Here, WNT5A is linked to psoriasis.